Sparrow Pharmaceuticals’ PROST! Adds a Fourth Cohort
By Daniella Parra Sparrow Pharmaceuticals continues its PROST! Phase 2 clinical trial for treating polymyalgia rheumatica (PMR) with SPI-62 and prednisolone, adding a fourth cohort, they said. PMR, an autoimmune disorder common among the elderly, traditionally treated with steroids like...